Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Laura Q.M. Chow(The University of Texas at Austin), Tanguy Y. Seiwert(Georgetown University), Makoto Tahara(National Cancer Center Hospital East), Dung T. Le(Johns Hopkins University), Barbara Burtness(Yale University), Ranee Mehra(University of Maryland, Baltimore), Joseph P. Eder(Yale Cancer Center), Ravit Geva(Tel Aviv Sourasky Medical Center), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Raanan Berger(Tel Aviv University), Kei Muro(Aichi Cancer Center), Deepti Aurora-Garg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert I. Haddad(Georgetown University), Hyun Cheol Chung(Yonsei University), Bhumsuk Keam(Seoul National University), Jared Weiss(Georgetown University), Chia‐Chi Lin(National Taipei University of Technology), Amit Mahipal(Dana-Farber Cancer Institute), Jonathan D. Cheng(Princeton University), Mark Ayers(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 31
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k